蒂亚美特G作为多囊性脏疾病的潜在治疗方法
Wen-Cheng Su1, Chi-Feng Hung2, Yi-Chieh Wang3
1Department of Medical Laboratory Science and Biotechnology, Yuan Pei University of Medical Technology, Hsinchu, Taiwan, R.O.C.
在多囊性病 (PKD) 中,O-GlcNAcylation 的下调,并影响多囊性病1 (PC1) 的稳定性. 在PKD小鼠中,用thiamet G抑制O-GlcNAcase减少了囊的形成,这表明O-GlcNAcylation是治疗标.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 自体主导多囊性病 (ADPKD) 是由Pkd1突变引起的常见遗传疾病,导致囊和功能衰竭.
- 目前没有针对ADPKD的预防治疗方法.
- 影响P1 (PC1) 突变是大多数ADPKD病例的原因.
研究的目的:
- 研究O-GlcNAcylation在多囊性病 (PKD) 进展中的作用.
- 检查O-GlcNAcase (OGA) 抑制对PKD模型的影响.
主要方法:
- 使用Pkd1-敲除小鼠和细胞来研究O-GlcNAcylation.
- 向PKD小鼠使用OGA抑制剂thiamet G进行治疗.
主要成果:
- 在Pkd1-沉默小鼠脏中,O-GlcNAcylation和O-GlcNAc转移酶 (OGT) 降低.
- O-GlcNAcylation影响PC1的C端细胞质尾巴 (CTT) 的稳定性和功能.
- 在PKD小鼠中,thiamet G治疗减少了脏囊的形成.
结论:
- O-GlcNAcylation 在PKD囊发育中起着独特的作用.
- O-GlcNAcylation 在治疗PKD方面是一个潜在的治疗标.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
08:46Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chronic Kidney Disease I: Introduction
Acute Kidney Injury V: Interprofessional Care
Urinary Tract Calculi III: Medical Management
